[{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"OSR Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BAL0891","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"ReiThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"SJ-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"4","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"}]

Find Clinical Drug Pipeline Developments & Deals by SillaJen, Inc

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Through the partnership, ReiThera will leverage its expertise to conduct advanced development & production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 24, 2025

                          Lead Product(s) : SJ-600

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : ReiThera

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          April 22, 2024

                          Lead Product(s) : BAL0891,Carboplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : OSR Holdings

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for metastatic or unresectable renal cell carcinoma.

                          Product Name : Pexa-Vec

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          March 27, 2024

                          Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : BAL0891 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 15, 2023

                          Lead Product(s) : BAL0891

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : BAL0891 is a potential first-in-class mitotic checkpoint inhibitor that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase and pol...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : $10.0 million

                          December 19, 2022

                          Lead Product(s) : BAL0891

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Basilea Pharmaceutica

                          Deal Size : $14.0 million

                          Deal Type : Agreement

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The agreement for a novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, demonstrates the commitment to enhance lives of patients suffering from advanced solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          September 19, 2022

                          Lead Product(s) : BAL0891

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Basilea Pharmaceutica

                          Deal Size : $334.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Pexa Vec

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          September 26, 2017

                          Lead Product(s) : Pexastimogene devacirepvec

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Pexa Vec

                          Product Type : Microorganism

                          Upfront Cash : Inapplicable

                          September 29, 2015

                          Lead Product(s) : Pexastimogene devacirepvec

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 10, 2012

                          Lead Product(s) : JX-594

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 15, 2011

                          Lead Product(s) : JX-594

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Transgene

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank